Uremia Clinical Trial
Official title:
Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan
The linkage between viral hepatitis and renal failure is complex. The current study aims to exlore the long-term prevalence of viral hepatitis among uremic patients in Taiwan
Patients are prospectively recruited from 15 hemodialysis units including one medical center, 3 satellite hospitals and 11 local clinics in Taiwan. Patients who provided informed consents for blood tests including genetic study related to HCV spontaneous seroclearance are enrolled for analysis. All the eligible subjects are tested for both HCV antibodies (third-generation, enzyme immunoassay; Abbott Laboratories, North Chicago, IL) and hepatitis B surface antigen (HBsAg). HCV RNA is tested by polymerase chain reaction (Cobas Amplicor Hepatitis C Virus Test, V.2.0; Roche Diagnostics, Branchburg, New Jersey, USA; detection limit: 50 IU/ml) twice for at least 6 months apart if anti-HCV is positive to ensure chronicity of HCV infection. HBsAg is quantified with the use of a standard quantitative chemiluminescent microparticle immunoassay (ARCHITECT HBsAg, Abbott Diagnostics). The concentration of HBsAg in the specimen is determined using a previously generated Architect HBsAg calibration curve (range, 0.05-250 IU/mL). Samples with serum HBsAg titer >250 IU/mL were diluted at 1:20 and 1:500 with the Architect HBsAg diluent and retested to expand the upper limit of the dynamic range from 250 to 125,000 IU/mL. Serum HBV DNA is determined by a standardized automated quantitative PCR assay (Cobas Amplicor HBV Monitor; Roche Diagnostics; detection limit 200 copies/ml) if patients are seropositive for HBsAg. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT00577967 -
Gabapentin - A Solution to Uremic Pruritus?
|
N/A | |
| Completed |
NCT01583309 -
Effects of Convective Therapies in Dialysis Patients
|
Phase 3 | |
| Completed |
NCT03437538 -
Reduction Ratio and Clearance During Hemodialysis With MCO-filter Compared to HDF With Standard High-flux Filter
|
N/A | |
| Completed |
NCT00649298 -
A Clinical Trial of IntensiVE Dialysis
|
Phase 4 | |
| Completed |
NCT05750875 -
Gabapentin Versus Loratadine in Uremic Pruritus
|
Phase 4 | |
| Recruiting |
NCT01408797 -
Clonal Deletion on Living-Relative Donor Kidney Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT01267760 -
Clinical and Biochemical Effects of Multipass Hemodialysis
|
Phase 2 | |
| Recruiting |
NCT00375635 -
Removal of Protein Bound Uremic Toxins by Modified Plasma Separation and Adsorption Combined With Hemodialysis
|
N/A | |
| Recruiting |
NCT05076318 -
Dysregulated Urea-synthesis at Terminal Uremia
|
N/A | |
| Completed |
NCT05899283 -
A Comparative Study of Two Kinds of Hemodialysis Filters
|
N/A | |
| Completed |
NCT04768309 -
Impact of Intestinal Microbiota on Uremic Toxins Productions
|
N/A | |
| Not yet recruiting |
NCT05386433 -
Paxlovid in the Treatment of COVID-19 Patients With Uremia
|
Early Phase 1 | |
| Completed |
NCT01391884 -
Elimination of Incretin Hormones in Patients With Severe Kidney Failure
|
N/A | |
| Completed |
NCT00442819 -
Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney
|
Phase 4 | |
| Not yet recruiting |
NCT02266238 -
Stenosis of Arteria-Venous Fistula in Maintenance Hemodialysis Patients: Early Intervention Trial
|
N/A | |
| Completed |
NCT00388648 -
Very Low Protein Diet or Dialysis in Uremic Elderly?
|
Phase 4 | |
| Withdrawn |
NCT03416192 -
12 Weeks of Hemodialysis With Medium Cut-Off Filter Compared to Hemodiafiltration With Standard High-flux Filter.
|
N/A | |
| Recruiting |
NCT02446535 -
Probing the Dry Weight (DW) by Bioimpedance (BIA): Which is the Gold Standard Between Clinical DW and BIA DW?
|
N/A | |
| Recruiting |
NCT02606955 -
Probing the Dry Weight by Bioimpedance: The Resistance Stabilization Test
|
N/A | |
| Completed |
NCT02050139 -
L-Cysteine in Peritoneal Dialysis
|
Phase 2 |